Adagio Therapeutics Inc Forecast, price target & analysts
Adagio Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Adagio Therapeutics Inc Classifications & Recommendation:
Adagio Therapeutics Inc Price Target
| Target Price | $5.10 |
| Price | $2.35 |
| Potential |
117.02%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Adagio Therapeutics Inc 2026 .
The average Adagio Therapeutics Inc target price is $5.10.
This is
117.02%
register free of charge
$10.50
346.81%
register free of charge
$2.02
14.04%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Adagio Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adagio Therapeutics Inc stock has an average upside potential 2026 of
117.02%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 25.38 | 51.30 |
| 102.14% | ||
| EBITDA Margin | -691.13% | -104.98% |
| 84.81% | ||
| Net Margin | -669.54% | -187.57% |
| 71.99% |
5 Analysts have issued a sales forecast Adagio Therapeutics Inc 2025 . The average Adagio Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Adagio Therapeutics Inc EBITDA forecast 2025. The average Adagio Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Adagio Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Adagio Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.43 | -0.45 |
| 20.99% | 68.53% | |
| P/E | negative | |
| EV/Sales | 9.02 |
5 Analysts have issued a Adagio Therapeutics Inc forecast for earnings per share. The average Adagio Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Adagio Therapeutics Inc...
Current Adagio Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 06 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Oct 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 27 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 06 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Oct 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 27 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 19 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
